JPWO2019243159A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019243159A5 JPWO2019243159A5 JP2020568439A JP2020568439A JPWO2019243159A5 JP WO2019243159 A5 JPWO2019243159 A5 JP WO2019243159A5 JP 2020568439 A JP2020568439 A JP 2020568439A JP 2020568439 A JP2020568439 A JP 2020568439A JP WO2019243159 A5 JPWO2019243159 A5 JP WO2019243159A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- salt
- solvate
- indicated
- variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 64
- 239000012453 solvate Substances 0.000 claims 62
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 28
- 239000012634 fragment Substances 0.000 claims 26
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 12
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 12
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000002619 cancer immunotherapy Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18178299 | 2018-06-18 | ||
| EP18178299.6 | 2018-06-18 | ||
| PCT/EP2019/065517 WO2019243159A1 (de) | 2018-06-18 | 2019-06-13 | Gegen cxcr5 gerichtete binder-wirkstoff-konjugate mit enzymatisch spaltbaren linkern und verbessertem wirkungsprofil |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527640A JP2021527640A (ja) | 2021-10-14 |
| JPWO2019243159A5 true JPWO2019243159A5 (https=) | 2022-06-21 |
| JP2021527640A5 JP2021527640A5 (https=) | 2022-06-21 |
Family
ID=62705502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568439A Pending JP2021527640A (ja) | 2018-06-18 | 2019-06-13 | 酵素的に切断可能なリンカーおよび改善された活性プロファイルを有する、cxcr5に対して向けられるバインダー/活性薬剤複合体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210275686A1 (https=) |
| EP (1) | EP3806908A1 (https=) |
| JP (1) | JP2021527640A (https=) |
| KR (1) | KR20210033470A (https=) |
| CN (1) | CN112601553A (https=) |
| AU (1) | AU2019289506A1 (https=) |
| BR (1) | BR112020025718A2 (https=) |
| CA (1) | CA3103327A1 (https=) |
| EA (1) | EA202190059A1 (https=) |
| IL (1) | IL279400A (https=) |
| MA (1) | MA71421A (https=) |
| MX (1) | MX2020013832A (https=) |
| SG (1) | SG11202012608VA (https=) |
| WO (1) | WO2019243159A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2751512C2 (ru) | 2015-06-22 | 2021-07-14 | Байер Фарма Акциенгезельшафт | Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы |
| RU2018102358A (ru) | 2015-06-23 | 2019-07-25 | Байер Фарма Акциенгезельшафт | Нацеленные конъюгаты ksp ингибиторов |
| AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
| CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤を有する特異的抗体-薬物コンジュゲート(adc) |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| CN115400223B (zh) * | 2022-09-29 | 2024-11-22 | 山东大学 | 一种二茂铁和tlr7/8激动剂共连接纳米粒及其制备方法和应用 |
| AR134514A1 (es) | 2023-12-01 | 2026-01-21 | Gilead Sciences Inc | Proteína de fusión anti-fap-ligera y uso de esta |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| GB8905592D0 (en) | 1989-03-10 | 1989-04-19 | Gkn Technology Ltd | Automatic length adjuster |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| AU2002365195A1 (en) | 2001-07-12 | 2003-07-30 | Incyte Genomics, Inc. | Intracellular signaling molecules |
| SG114505A1 (en) | 2001-10-17 | 2005-09-28 | First Cube Pte Ltd | System and method for facilitating delivery and return service |
| AU2002363960B2 (en) | 2001-12-06 | 2008-07-10 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| EP1620092A4 (en) | 2003-05-07 | 2008-04-16 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| US7939539B2 (en) | 2003-11-25 | 2011-05-10 | Novartis Vaccines And Diagnostics, Inc. | Quinazolinone compounds as anticancer agents |
| DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| US7662581B1 (en) | 2003-12-18 | 2010-02-16 | Novartis Vaccines And Diagnostics, Inc. | Eg5 co-crystals |
| KR101170925B1 (ko) | 2004-06-18 | 2012-08-07 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 암 치료용 키네신 방추 단백질 (ksp) 억제제로서의n-(1-(1-벤질-4-페닐-1h-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물 |
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| US20100093767A1 (en) | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
| TW200800951A (en) | 2005-08-09 | 2008-01-01 | Novartis Ag | Substituted imidazole compounds as KSP inhibitors |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| AU2008205169B2 (en) | 2007-01-05 | 2012-02-02 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5) |
| CN111909273B (zh) * | 2007-08-29 | 2024-03-26 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2968591A1 (en) | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
| JP6522585B2 (ja) * | 2013-05-02 | 2019-05-29 | アレス トレーディング ソシエテ アノニム | Cxcr5に対するモノクローナル抗体 |
| PL3086814T3 (pl) | 2013-12-23 | 2020-12-28 | Bayer Pharma Aktiengesellschaft | Koniugaty środka wiążącego (ADC) z inhibitorami KSP |
| CN107635586B (zh) | 2014-12-15 | 2021-09-24 | 拜耳医药股份有限公司 | Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc) |
| RU2751512C2 (ru) * | 2015-06-22 | 2021-07-14 | Байер Фарма Акциенгезельшафт | Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы |
| AU2017236431A1 (en) * | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| JP7066714B2 (ja) * | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
-
2019
- 2019-06-13 JP JP2020568439A patent/JP2021527640A/ja active Pending
- 2019-06-13 CA CA3103327A patent/CA3103327A1/en active Pending
- 2019-06-13 MA MA71421A patent/MA71421A/fr unknown
- 2019-06-13 KR KR1020217001448A patent/KR20210033470A/ko not_active Ceased
- 2019-06-13 SG SG11202012608VA patent/SG11202012608VA/en unknown
- 2019-06-13 CN CN201980054004.9A patent/CN112601553A/zh active Pending
- 2019-06-13 AU AU2019289506A patent/AU2019289506A1/en not_active Abandoned
- 2019-06-13 WO PCT/EP2019/065517 patent/WO2019243159A1/de not_active Ceased
- 2019-06-13 MX MX2020013832A patent/MX2020013832A/es unknown
- 2019-06-13 EA EA202190059A patent/EA202190059A1/ru unknown
- 2019-06-13 BR BR112020025718-4A patent/BR112020025718A2/pt not_active IP Right Cessation
- 2019-06-13 EP EP19729312.9A patent/EP3806908A1/de not_active Withdrawn
- 2019-06-13 US US17/253,086 patent/US20210275686A1/en not_active Abandoned
-
2020
- 2020-12-13 IL IL279400A patent/IL279400A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527640A5 (https=) | ||
| US20250346661A1 (en) | Dual specific antibodies | |
| RU2636043C2 (ru) | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения | |
| US8889130B2 (en) | Treatment of osteoarthritis and pain | |
| JP2024150445A5 (https=) | ||
| JP2019146572A5 (https=) | ||
| JPWO2021183359A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| RU2019122802A (ru) | Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы | |
| JP2019532056A5 (https=) | ||
| JP2009532336A5 (https=) | ||
| JP2025183307A5 (https=) | ||
| JP2003525061A5 (https=) | ||
| JP2017534253A5 (https=) | ||
| JP2014524902A5 (https=) | ||
| JP2016538318A5 (https=) | ||
| CN110022903B (zh) | Met抗体药物缀合物 | |
| JPWO2021213434A5 (https=) | ||
| JP2012532851A5 (https=) | ||
| JPWO2019243159A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| EP3504244A1 (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| JPWO2023026791A5 (https=) | ||
| JP2025015580A5 (https=) |